The FDA Withdraws Emergency Approval for the Malaria Drug Hydroxychloroquine
On Monday, June 15, 2020, the U.S. Food and Drug Administration removed the Emergency Authorization Use (EAU) of two malaria drugs to treat COVID-19, saying that they are “unlikely to be effective.”
Both hydroxychloroquine (brand name Plaquenil) and chloroquine were heavily promoted by President Trump after a handful of small, poorly controlled studies showed that they could work in treating the disease.
The primary objective of local, state, and federal response to COVID-19 is to minimize mortality and mitigate explosive demand for acute health-care services related to COVID-19 complications, especially those that require care in intensive care units.
For 15 years, I have walked the halls of Congress. I did not take a class or even receive any helpful tips before embarking on this endeavor, but over time, I acquired valuable experience on the protocol and inner workings of Congress.
